BRD3731
Modify Date: 2024-01-10 18:05:49
BRD3731 structure
|
Common Name | BRD3731 | ||
|---|---|---|---|---|
| CAS Number | 2056262-07-6 | Molecular Weight | 377.52 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C24H31N3O | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of BRD3731BRD3731 is a selective GSK3β inhibitor, with IC50s of 15 nM and 215 nM for GSK3β and GSK3α, respectively. BRD3731 can be used for the research of a mood disorder, post-traumatic stress disorder (PTSD), psychiatric disorder, diabetes, and neurodegenerative disorder[1]. |
| Name | BRD3731 |
|---|
| Description | BRD3731 is a selective GSK3β inhibitor, with IC50s of 15 nM and 215 nM for GSK3β and GSK3α, respectively. BRD3731 can be used for the research of a mood disorder, post-traumatic stress disorder (PTSD), psychiatric disorder, diabetes, and neurodegenerative disorder[1]. |
|---|---|
| Related Catalog | |
| Target |
GSK-3β:15 nM (IC50) GSK-3α:215 nM (IC50) |
| In Vitro | BRD3731 is a GSK3β- selective inhibitor extracted from patent US20160375006A1, compound example 272[1]. BRD3731 (1-10 μM; 24 hours) inhibits the phosphorylation of CRMP2 in SH-SY5Y cells[1]. BRD3731 (20 μM; 24 hours) decreases β-catenin S33/37/T41 phosphorylation and induces β-catenin S675 phosphorylation inHL-60 cells[2]. BRD3731 (10-20 μM; 7-10 days) impairs colony formation in TF-1 and increases colony forming ability in the MV4–11 cell line[2] |
| In Vivo | BRD3731 (30 mg/kg; i.p.) reduces audiogenic seizures in Fmr1 KO mice[1]. |
| References |
[1]. Edward Scolnick, et al. Uses of paralog-selective inhibitors of gsk3 kinases. US20160375006A1. |
| Molecular Formula | C24H31N3O |
|---|---|
| Molecular Weight | 377.52 |